Ticagrelor-Induced Syncope/Bradyarrhythmia

Ticagrelor (BRILINTA®) is a very commonly used oral antiplatelet agent in acute coronary syndrome and after percutaneous coronary intervention (PCI). It is a reversible, direct inhibitor of the adenosine diphosphate (ADP) P2Y12 receptor. Most of the patients tolerate the drug well but it is known to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kotaru, VeeraPavan, Kalavakunta, Jagadeesh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899257/
https://www.ncbi.nlm.nih.gov/pubmed/33633903
http://dx.doi.org/10.7759/cureus.12874
_version_ 1783654018706309120
author Kotaru, VeeraPavan
Kalavakunta, Jagadeesh K
author_facet Kotaru, VeeraPavan
Kalavakunta, Jagadeesh K
author_sort Kotaru, VeeraPavan
collection PubMed
description Ticagrelor (BRILINTA®) is a very commonly used oral antiplatelet agent in acute coronary syndrome and after percutaneous coronary intervention (PCI). It is a reversible, direct inhibitor of the adenosine diphosphate (ADP) P2Y12 receptor. Most of the patients tolerate the drug well but it is known to cause brady arrhythmias and ventricular pauses, the exact mechanism of which is unclear. We present a case of acute coronary syndrome/unstable angina in a 58-year-old Caucasian gentleman requiring cardiac catheterization and PCI with drug eluting stent deployment and syncope following Ticagrelor loading from long ventricular pauses.
format Online
Article
Text
id pubmed-7899257
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-78992572021-02-24 Ticagrelor-Induced Syncope/Bradyarrhythmia Kotaru, VeeraPavan Kalavakunta, Jagadeesh K Cureus Cardiology Ticagrelor (BRILINTA®) is a very commonly used oral antiplatelet agent in acute coronary syndrome and after percutaneous coronary intervention (PCI). It is a reversible, direct inhibitor of the adenosine diphosphate (ADP) P2Y12 receptor. Most of the patients tolerate the drug well but it is known to cause brady arrhythmias and ventricular pauses, the exact mechanism of which is unclear. We present a case of acute coronary syndrome/unstable angina in a 58-year-old Caucasian gentleman requiring cardiac catheterization and PCI with drug eluting stent deployment and syncope following Ticagrelor loading from long ventricular pauses. Cureus 2021-01-23 /pmc/articles/PMC7899257/ /pubmed/33633903 http://dx.doi.org/10.7759/cureus.12874 Text en Copyright © 2021, Kotaru et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Cardiology
Kotaru, VeeraPavan
Kalavakunta, Jagadeesh K
Ticagrelor-Induced Syncope/Bradyarrhythmia
title Ticagrelor-Induced Syncope/Bradyarrhythmia
title_full Ticagrelor-Induced Syncope/Bradyarrhythmia
title_fullStr Ticagrelor-Induced Syncope/Bradyarrhythmia
title_full_unstemmed Ticagrelor-Induced Syncope/Bradyarrhythmia
title_short Ticagrelor-Induced Syncope/Bradyarrhythmia
title_sort ticagrelor-induced syncope/bradyarrhythmia
topic Cardiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7899257/
https://www.ncbi.nlm.nih.gov/pubmed/33633903
http://dx.doi.org/10.7759/cureus.12874
work_keys_str_mv AT kotaruveerapavan ticagrelorinducedsyncopebradyarrhythmia
AT kalavakuntajagadeeshk ticagrelorinducedsyncopebradyarrhythmia

Ejemplares similares